Concerns Over mRNA Vaccines Rise

Officials, along with media and pharmaceutical representatives, have advocated for mRNA vaccines that were quickly introduced during the pandemic as “safe and effective.” However, many Americans who faced criticism, censorship, and even job losses over vaccine hesitancy still feel unsettled.

Health Secretary Robert F. Kennedy Jr. expressed skepticism, claiming that mRNA vaccines “do not interfere with transmission.” In 2021, he even stated that the Covid-19 vaccine might be “the most deadly vaccine ever made.” Recently, he announced that the U.S. Department of Health and Human Services (HHS) is scaling back on mRNA vaccine initiatives.

He remarked, “Vaccinations paradoxically encourage new mutations,” highlighting concerns about the vaccines encouraging viral evolution. Daniel Horowitz, a senior editor at Blaze News, pointed out that while there are worries regarding RFK’s focus on health food trends, the recent pause in mRNA research indicates a continued concern about its dangers.

Kennedy reported that multiple mRNA vaccine development projects have been reassessed and canceled, primarily aimed at the flu or Covid-19. Yet, experience shows that these vaccines often falter against upper respiratory infections.

He pointed out that mRNA only encodes a small part of the virus’s protein, which means that one mutation can render the vaccine ineffective. “This phenomenon leads to what’s known as ‘antigen shift,'” he explained. The ongoing mutability of the virus can extend the pandemic as it evolves to evade vaccine protection.

Following consultations with experts and reviews of the relevant data, HHS concluded that the risks of mRNA technology outweigh the benefits regarding respiratory viruses, according to Kennedy.

HHS is winding down its mRNA projects as part of the contract with Emory University and Tiva Biotechnology, alongside ceasing collaboration with other firms like Luminary Labs and Seqirus. The agency has decided to halt all mRNA-related investments globally, signaling that future mRNA projects will not be supported, though some existing contracts may still proceed.

Kennedy emphasized, “Let me be perfectly clear, HHS supports safe and effective vaccines for Americans who choose to get them. That’s why we’re looking for better alternatives beyond mRNA for respiratory viruses.”

Although he welcomed the cancellations, Horowitz questioned whether Kennedy would approve the current mRNA vaccines for Covid and RSV, as new approvals have emerged despite concerns about their effectiveness. He observed that some like Moderna continue to receive authorizations for new Covid and RSV vaccines.

This shift from HHS comes just weeks after Pfizer and Moderna requested updates on side effect warnings associated with mRNA vaccines. The FDA noted these manufacturers should incorporate information about unadjusted cardiac issues following vaccination in their communications.